Abstract:Hepatocellular carcinoma (HCC) is a common malignancy worldwide. Alpha-fetoprotein (AFP) is still the only serum biomarker widely used in clinical settings. However, approximately 40% of HCC patients exhibit normal AFP levels, including very early HCC and AFP-negative HCC; for these patients, serum AFP is not applicable as a biomarker of early detection. Thus, there is an urgent need to identify novel biomarkers for patients for whom disease cannot be diagnosed early. In this study, we screened and identified novel proteins in AFP-negative HCC and evaluated the feasibility of using autoantibodies to those protein to predict hepatocarcinogenesis. First, we screened and identified differentially expressed proteins between AFP-negative HCC tissue and adjacent non-tumor liver tissue using SWATH-MS proteome technology. In total, 2,506 proteins were identified with a global false discovery rate of 1%, of which 592 proteins were expressed differentially with 175 upregulated and 417 downregulated (adjusted p -value <0.05, fold-change FC ≥1.5 or ≤0.67) between the tumor and matched benign samples, including 14-3-3 zeta protein. For further serological verification, autoantibodies against 14-3-3 zeta in serum were evaluated using enzyme-linked immunosorbent, Western blotting, and indirect immunofluorescence assays. Five serial serum samples from one patient with AFP-negative HCC showed anti-14-3-3 zeta autoantibody in sera 9 months before the diagnosis of HCC, which gradually increased with an increase in the size of the nodule. Based on these findings, we detected the prevalence of serum anti-14-3-3 zeta autoantibody in liver cirrhosis (LC) patients, which is commonly considered a premalignant liver disease of HCC. We found that the prevalence of autoantibodies against 14-3-3 zeta protein was 16.1% (15/93) in LC patient sera, which was significantly higher than that in patients with chronic hepatitis (0/75, p = 0.000) and normal human sera (1/60, 1.7%, p = 0.01). Therefore, we suggest that anti-14-3-3 zeta autoantibody might be a biomarker for predicting hepatocarcinogenesis. Further follow-up and research of patients with positive autoantibodies will be continued to confirm the relationship between anti-14-3-3 zeta autoantibody and hepatocarcinogenesis.

P53 Autoantibodies Predict Subsequent Development of Cancer

The Potential for Serum P53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer

B-360 Usefulness of the Ratios of CYFRA21-1 and P53 Autoantibody Immune Complexes to Their Free Antigens in Lung Cancer

Autoantibody recognition mechanisms of p53 epitopes

Serum p53 antibody detection in patients with impaired lung function

Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival

Five Tumor-Associated Autoantibodies Expression Levels in Serum Predict Lung Cancer and Associate with Poor Outcome.

Prognostic Significance of the Tumor Suppressor Protein P53 Gene in Childhood Acute Lymphoblastic Leukemia.

A Panel of Tumor-associated Autoantibodies for the Detection of Early-stage Breast Cancer

[Peripheral Blood Mutated P53 DNA and Its Clinical Value in Human Breast Cancer].

Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma

Nuclear immunoreaction of p53 as related to prognosis of breast cancer

Prospective Evaluation of 64 Serum Autoantibodies As Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting

Serum Anti-14-3-3 Zeta Autoantibody as a Biomarker for Predicting Hepatocarcinogenesis

Autoantibodies to PAX5, PTCH1, and GNA11 as Serological Biomarkers in the Detection of Hepatocellular Carcinoma in Hispanic Americans

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer

Retracted: P53 Mutation in Plasma Dna and Its Prognostic Value in Breast Cancer Patients (retracted Article. See Vol 8, Pg 3027, 2002)

Immunohistochemistry of p53 surrogates TP53 mutation as an accurate predictor for early-relapse of surgically resected stage I-III lung adenocarcinoma

Antigen-Mimic Nanoparticles in Ultrasensitive on-Chip Integrated Anti-p53 Antibody Quantification

p53 mutation in plasma DNA and its prognostic value in breast cancer patients.

Blood Autoantibodies Against Tumor-Associated Antigens As Biomarkers in Early Detection of Colorectal Cancer